Literature DB >> 22033491

Specific deletion of TRAF3 in B lymphocytes leads to B-lymphoma development in mice.

C R Moore, Y Liu, C Shao, L R Covey, H C Morse, P Xie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22033491      PMCID： PMC3433763          DOI： 10.1038/leu.2011.309

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

Review 1.  The Bcl-2 family: roles in cell survival and oncogenesis.

Authors:  Suzanne Cory; David C S Huang; Jerry M Adams
Journal:  Oncogene       Date:  2003-11-24       Impact factor: 9.867

2.  Biallelic inactivation of TRAF3 in a subset of B-cell lymphomas with interstitial del(14)(q24.1q32.33).

Authors:  I Nagel; S Bug; H Tönnies; O Ammerpohl; J Richter; I Vater; E Callet-Bauchu; M J Calasanz; J A Martinez-Climent; C Bastard; M Salido; E Schroers; J I Martin-Subero; S Gesk; L Harder; A Majid; M J S Dyer; R Siebert
Journal:  Leukemia       Date:  2009-08-20       Impact factor: 11.528

Review 3.  Autoimmune disorders and lymphoma.

Authors:  F Caligaris-Cappio
Journal:  Ann Oncol       Date:  2008-06       Impact factor: 32.976

4.  Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways.

Authors:  Takayuki Ikezoe; Yang Yang; Kentaro Bandobashi; Tsuyako Saito; Shigeki Takemoto; Hisanori Machida; Kazuto Togitani; H Phillip Koeffler; Hirokuni Taguchi
Journal:  Mol Cancer Ther       Date:  2005-04       Impact factor: 6.261

Review 5.  The role of the BAFF/APRIL system in B cell homeostasis and lymphoid cancers.

Authors:  Fabienne Mackay; Stuart G Tangye
Journal:  Curr Opin Pharmacol       Date:  2004-08       Impact factor: 5.547

6.  Bethesda proposals for classification of lymphoid neoplasms in mice.

Authors:  Herbert C Morse; Miriam R Anver; Torgny N Fredrickson; Diana C Haines; Alan W Harris; Nancy L Harris; Elaine S Jaffe; Scott C Kogan; Ian C M MacLennan; Paul K Pattengale; Jerrold M Ward
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

7.  Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs.

Authors:  Ping Xie; Laura L Stunz; Karen D Larison; Baoli Yang; Gail A Bishop
Journal:  Immunity       Date:  2007-08       Impact factor: 31.745

8.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

Authors:  Jonathan J Keats; Rafael Fonseca; Marta Chesi; Roelandt Schop; Angela Baker; Wee-Joo Chng; Scott Van Wier; Rodger Tiedemann; Chang-Xin Shi; Michael Sebag; Esteban Braggio; Travis Henry; Yuan-Xiao Zhu; Homer Fogle; Tammy Price-Troska; Gregory Ahmann; Catherine Mancini; Leslie A Brents; Shaji Kumar; Philip Greipp; Angela Dispenzieri; Barb Bryant; George Mulligan; Laurakay Bruhn; Michael Barrett; Riccardo Valdez; Jeff Trent; A Keith Stewart; John Carpten; P Leif Bergsagel
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

9.  TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor.

Authors:  Sandra Gardam; Frederic Sierro; Antony Basten; Fabienne Mackay; Robert Brink
Journal:  Immunity       Date:  2008-02-28       Impact factor: 31.745

10.  Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

Authors:  Christina M Annunziata; R Eric Davis; Yulia Demchenko; William Bellamy; Ana Gabrea; Fenghuang Zhan; Georg Lenz; Ichiro Hanamura; George Wright; Wenming Xiao; Sandeep Dave; Elaine M Hurt; Bruce Tan; Hong Zhao; Owen Stephens; Madhumita Santra; David R Williams; Lenny Dang; Bart Barlogie; John D Shaughnessy; W Michael Kuehl; Louis M Staudt
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743
View more
  39 in total

1.  TRAF3 Acts as a Checkpoint of B Cell Receptor Signaling to Control Antibody Class Switch Recombination and Anergy.

Authors:  Zhangguo Chen; Alexandra Krinsky; Rachel A Woolaver; Xiaoguang Wang; Samantha M Y Chen; Vince Popolizio; Ping Xie; Jing H Wang
Journal:  J Immunol       Date:  2020-06-26       Impact factor: 5.422

2.  Nuclear TRAF3 is a negative regulator of CREB in B cells.

Authors:  Nurbek Mambetsariev; Wai W Lin; Laura L Stunz; Brett M Hanson; Joanne M Hildebrand; Gail A Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-11       Impact factor: 11.205

3.  Expression and function of a novel isoform of Sox5 in malignant B cells.

Authors:  Shanique K E Edwards; Anand Desai; Yan Liu; Carissa R Moore; Ping Xie
Journal:  Leuk Res       Date:  2013-12-25       Impact factor: 3.156

4.  The oncogenic membrane protein LMP1 sequesters TRAF3 in B-cell lymphoma cells to produce functional TRAF3 deficiency.

Authors:  Pradeep Bangalore-Prakash; Laura L Stunz; Nurbek Mambetsariev; Amy L Whillock; Bruce S Hostager; Gail A Bishop
Journal:  Blood Adv       Date:  2017-12-18

5.  An oncogenic role for alternative NF-κB signaling in DLBCL revealed upon deregulated BCL6 expression.

Authors:  Baochun Zhang; Dinis Pedro Calado; Zhe Wang; Sebastian Fröhler; Karl Köchert; Yu Qian; Sergei B Koralov; Marc Schmidt-Supprian; Yoshiteru Sasaki; Christine Unitt; Scott Rodig; Wei Chen; Riccardo Dalla-Favera; Frederick W Alt; Laura Pasqualucci; Klaus Rajewsky
Journal:  Cell Rep       Date:  2015-04-23       Impact factor: 9.423

6.  Myeloid cell TRAF3 regulates immune responses and inhibits inflammation and tumor development in mice.

Authors:  Almin I Lalani; Carissa R Moore; Chang Luo; Benjamin Z Kreider; Yan Liu; Herbert C Morse; Ping Xie
Journal:  J Immunol       Date:  2014-11-24       Impact factor: 5.422

Review 7.  Roles for TNF-receptor associated factor 3 (TRAF3) in lymphocyte functions.

Authors:  Zuoan Yi; Wai Wai Lin; Laura L Stunz; Gail A Bishop
Journal:  Cytokine Growth Factor Rev       Date:  2013-12-25       Impact factor: 7.638

8.  The adaptor protein TRAF3 inhibits interleukin-6 receptor signaling in B cells to limit plasma cell development.

Authors:  Wai W Lin; Zuoan Yi; Laura L Stunz; Christian J Maine; Linda A Sherman; Gail A Bishop
Journal:  Sci Signal       Date:  2015-09-01       Impact factor: 8.192

9.  Signaling mechanisms of bortezomib in TRAF3-deficient mouse B lymphoma and human multiple myeloma cells.

Authors:  Shanique K E Edwards; Yeming Han; Yingying Liu; Benjamin Z Kreider; Yan Liu; Sukhdeep Grewal; Anand Desai; Jacqueline Baron; Carissa R Moore; Chang Luo; Ping Xie
Journal:  Leuk Res       Date:  2015-12-19       Impact factor: 3.156

10.  The TRAF3 adaptor protein drives proliferation of anaplastic large cell lymphoma cells by regulating multiple signaling pathways.

Authors:  Israel Muro; Gloria Fang; Kacie A Gardella; Indra M Mahajan; Casey W Wright
Journal:  Cell Cycle       Date:  2014-04-16       Impact factor: 4.534
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.